New Features and Design Optimize Care and Process Efficiencies for
Clinicians in both the Sleep Center and Homecare Environments
IRVINE, Calif., June 9 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI),
the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and
Low-Perfusion pulse oximetry, announced today the debut of its new compact,
lightweight Rad-8 pulse oximeter at SLEEP 2009, the 23rd Annual Meeting of the
Associated Professional Sleep Societies (APSS), June 6-11, 2009 in Seattle,
Washington. Newly redesigned with greater clinical efficiency in mind, the new
Masimo Rad-8 has a streamlined look and a host of easy-to-use special features
that enable sleep clinicians to more effectively and efficiently monitor,
diagnose, and care for patients with sleep disorders.
According to the National Institutes of Health (NIH), more than 70 million
Americans are affected by chronic sleep disorders. Sleep apnea is a very
common yet serious sleep disorder where a person's breathing is uncontrollably
and repeatedly interrupted during sleep, resulting in very brief or prolonged
periods of oxygen deprivation. Serious problems can result from the oxygen
deprivation of sleep apnea--including: heart disease, high blood pressure and
learning/memory problems--and, if left untreated, sleep apnea can be
life-threatening.(1)
Pulse oximetry is the standard method for assessing oxygenation in sleep
testing and, as such, plays a critical role in treatment decisions, including
whether to administer Continuous Positive Airway Pressure (CPAP) therapy or
perform surgery. Inaccurate pulse oximetry data can have serious implications
because false pulse oximetry desaturations can lead to misdiagnosis and
inappropriate treatment or surgery, while missed true desaturations can
prevent correct diagnosis and potentially lifesaving treatment. The new Rad-8
combines the unmatched sensitivity and specificity of Masimo SET(R)
Measure-Through Motion and Low-Perfusion pulse oximetry--clinically-proven to
reduce false alarms by over 90% and increase capture of true desaturation
events by 98%--with enhanced functionality to help clinicians better capture,
analyze, and report vital oxygen saturation, pulse rate, and perfusion data
for improved sleep disorder detection.
The superior fidelity of Masimo SET has been clinically-shown to
outperform other pulse oximeters in the accurate identification and
quantification of brief dips in oxygen saturation due to apneas and
hypopneas--an important marker and measure of severity for Obstructive Sleep
Apnea (OSA) diagnosis and treatment. In fact, previous research conducted at
Montreal Children's Hospital in Quebec found that using a Masimo pulse
oximeter with very short averaging time was not only more accurate in
detecting true desaturation events, including brief dips in oxygen saturation
as well as larger ones, but could also "significantly reduce workload and
improve reliability of desaturation detection" over other pulse oximeters.
Study findings confirmed that Masimo detected 98.6% of true desaturations,
while the N-395 detected only 45.3%, leading researchers to conclude that "the
sensitivity and motion artifact rejection characteristics of the Nellcor N-395
oximeter are not adequate for a pediatric sleep laboratory setting."(2)
And, based on clinician input, Rad-8 now features an intuitive
user-interface and easy menu navigation to save time and enable faster, easier
set-up, and operation, while one-touch quick access buttons allow clinicians
to engage special features in an instant. New user-selectable alarm settings
make it quick and easy for clinicians to set and save configurations for
specific patient monitoring needs and unique clinical applications. In
addition, 72-hour trending, configurable Sleep and Home modes, and enhanced
data collection/reporting compatibility make the new Rad-8 the ideal patient
monitoring solution for sleep center, home, sub-acute, and transport
applications.
(1) National Institutes of Health "Frontiers of Knowledge in Sleep and
Sleep Disorders: Opportunities for Improving Health and Quality of Life."
March 2004. http://www.nhlbi.nih.gov/about/ncsdr/research/research-a.htm
(2) Robert Brouillette, MD, Jacinthe Lavergne, RRT, Andra Leimanis, BSc,
Gillian Nixon, MB ChB, FRACP, Sylvia Ladan, RRT, Christine McGregor, RRT.
"Differences in Pulse Oximetry Technology can Affect Detection of
Sleep-Disordered Breathing in Children." Anesth Analg 2002; 94: S47-S53.
About Masimo
Masimo (NASDAQ: MASI) develops innovative monitoring technologies that
significantly improve patient care--helping solve "unsolvable" problems. In
1995, the company debuted Measure-Through Motion and Low-Perfusion pulse
oximetry, known as Masimo SET(R), which virtually eliminated false alarms and
increased pulse oximetry's ability to detect life-threatening events. More
than 100 independent and objective studies demonstrate Masimo SET provides the
most reliable SpO2 and pulse rate measurements even under the most challenging
clinical conditions, including patient motion and low peripheral perfusion. In
2005, Masimo introduced Masimo Rainbow SET(R) Pulse CO-Oximetry(TM), a
breakthrough noninvasive blood constituent monitoring platform that can
measure many blood constituents that previously required invasive procedures.
Masimo Rainbow SET continuously and noninvasively measures total hemoglobin
(SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(R)),
methemoglobin (SpMet(R)), and PVI(TM), in addition to oxyhemoglobin (SpO2),
pulse rate (PR), and perfusion index (PI), allowing early detection and
treatment of potentially life-threatening conditions. Founded in 1989, Masimo
has the mission of "Improving Patient Outcomes and Reducing Cost of Care by
Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, in connection with the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are based on current
expectations about future events affecting us and are subject to risks and
uncertainties, all of which are difficult to predict and many of which are
beyond our control and could cause our actual results to differ materially and
adversely from those expressed in our forward-looking statements as a result
of various risk factors, including, but not limited to: risks related to our
belief that the commercial availability of the new Rad-8 will serve to
increase adoption, market share and/or revenues for the company, risks that
Masimo SET sensitivity and specificity performance will be duplicated in other
studies and applications, risks related to our assumption that the new Rad-8
will enable clinicians to more effectively and efficiently monitor, diagnose,
and care for patients with sleep disorders, as well as other factors discussed
in the "Risk Factors" section of our Quarterly Report on Form 10-Q for the
fiscal quarter year ended April 4, 2009, filed with the Securities and
Exchange Commission ("SEC") on May 6, 2009, which may be obtained for free at
the SEC's website at www.sec.gov. Although we believe that the expectations
reflected in our forward-looking statements are reasonable, we do not know
whether our expectations will prove correct. All forward-looking statements
included in this press release are expressly qualified in their entirety by
the foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of today's
date. We do not undertake any obligation to update, amend or clarify these
forward-looking statements or the "Risk Factors" contained in our Quarterly
Report on Form 10-Q for the fiscal quarter ended April 4, 2009, whether as a
result of new information, future events or otherwise, except as may be
required under the applicable securities laws.
Contact:
Dana Banks
Masimo Corporation
949-297-7348
Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing
Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications,
Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57, Rad-9,
Rad-8, Rad-5, Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or
registered trademarks of Masimo Corporation. Other trademarks used herein are
the property of their respective owners.
SOURCE Masimo
Web Site: http://www.masimo.com